RIGEL PHARMACEUTICALS INC RIGL
We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.
TAVALISSE® (fostamatinib disodium hexahydrate) is our first FDA-approved product and is the only approved oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The product is also commercially available in Europe and the United Kingdom (UK) (as TAVLESSE), and in Japan, the Republic of Korea (Korea), Canada and Israel (as TAVALISSE) for the treatment of chronic ITP in adult patients.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M | $59.3M | $44.5M | $4.5M | $20.4M |
| Cost of revenue | $19.6M | $18.6M | $7.1M | $1.7M | $1.1M | $895.0K | $906.0K | $287.0K | — | — |
| Gross profit | $274.7M | $160.6M | $109.8M | $118.5M | $148.2M | $107.7M | $58.4M | $44.2M | — | — |
| R&D | $33.3M | $23.4M | $24.5M | — | — | — | — | — | — | — |
| SG&A | $115.9M | $113.1M | $105.7M | $112.5M | $91.9M | $76.6M | $74.6M | $70.0M | $37.8M | $20.9M |
| Total operating expenses | $168.8M | $155.1M | $137.4M | $175.8M | $161.7M | $137.6M | $128.4M | $117.2M | $84.1M | $90.1M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M | -$29.0M | -$69.1M | -$72.7M | -$79.6M | -$69.7M |
| Interest expense | $7.3M | $7.9M | $6.9M | $3.7M | $4.9M | $1.4M | $335.0K | — | — | — |
| Pre-tax income | $121.8M | $18.4M | -$25.1M | -$58.6M | -$17.3M | -$29.7M | -$66.9M | -$70.5M | -$78.0M | -$69.2M |
| Income tax | $245.2M | $881.0K | $0 | — | $605.0K | — | — | $0 | $0 | $0 |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M | -$29.7M | -$66.9M | -$70.5M | -$78.0M | -$69.2M |
| EPS, basic | 20.40 | 0.99 | -1.44 | -3.44 | -0.11 | -0.18 | -0.40 | — | — | — |
| EPS, diluted | 19.48 | 0.99 | -1.44 | -3.44 | -0.11 | -0.18 | -0.40 | -0.44 | -0.62 | -0.73 |
| Shares, diluted (wtd. avg.) | $18.8M | $17.7M | $17.4M | $17.0M | $170.5M | $168.8M | $167.4M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $40.6M | $56.7M | $32.8M | $24.5M | $18.9M | $30.4M | $22.5M | $76.3M | $38.3M | $17.6M |
| Short-term investments | $114.4M | $20.6M | $24.1M | $33.7M | $106.1M | $27.0M | $75.6M | $52.2M | $77.5M | $57.1M |
| Receivables | $51.8M | $41.6M | $30.6M | $40.3M | $15.5M | $16.0M | $10.1M | $4.1M | $0 | $0 |
| Inventory | $11.5M | $6.0M | $5.5M | $9.1M | $6.6M | $1.6M | $1.4M | $894.0K | — | — |
| Total current assets | $240.2M | $135.1M | $99.3M | $115.9M | $154.5M | $89.0M | $119.0M | $137.0M | $117.4M | $76.2M |
| Property, plant and equipment | $30.0K | $92.0K | $165.0K | $857.0K | $2.2M | $2.7M | $2.2M | $1.4M | $875.0K | $1.2M |
| Other intangibles | $24.7M | $27.1M | $13.9M | $14.9M | — | — | — | — | — | — |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M | $110.4M | $147.6M | $139.1M | $119.1M | $78.1M |
| Accounts payable | $7.2M | $3.3M | $7.1M | $22.5M | $3.8M | $3.7M | $4.2M | $6.4M | $2.6M | $5.6M |
| Total current liabilities | $99.2M | $63.3M | $53.3M | $65.2M | $63.6M | $40.8M | $58.2M | $27.7M | $18.3M | $22.6M |
| Long-term debt | $52.5M | $60.0M | $60.0M | $40.0M | $20.0M | $20.0M | $10.0M | — | — | — |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137.0M | — | — | — | — | — |
| Retained earnings | -$1.02B | -$1.39B | -$1.41B | -$1.38B | -$1.32B | -$1.31B | -$1.28B | -$1.21B | -$1.14B | -$1.06B |
| Total equity | $391.5M | $3.3M | -$28.6M | -$13.6M | $30.4M | $34.0M | $53.8M | $109.9M | $100.6M | $55.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M | -$52.2M | -$41.5M | -$58.8M | -$77.6M | -$75.9M |
| Depreciation and amortisation | $2.4M | $2.2M | $1.2M | $998.0K | $1.2M | $706.0K | $683.0K | $594.0K | $465.0K | $941.0K |
| Stock-based compensation | $12.7M | $12.4M | $8.8M | $12.4M | $9.5M | $7.3M | $9.1M | $7.7M | $6.0M | $7.3M |
| Capital expenditure | — | — | — | $450.0K | $627.0K | $1.3M | $1.5M | $1.1M | $164.0K | $804.0K |
| Investing cash flow | -$92.4M | $4.1M | -$4.3M | $72.8M | -$80.0M | $47.5M | -$23.7M | $25.0M | -$19.5M | $24.9M |
| Financing cash flow | $601.0K | -$11.6M | $18.4M | $6.5M | $62.7M | $12.6M | $11.4M | $71.9M | $117.7M | $25.2M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001034842-26-000015.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |